You can buy or sell Biocept and other stocks, options, ETFs, and crypto commission-free!
Biocept, Inc. Common Stock, also called Biocept, is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. Read More It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. The company utilizes cell enrichment and extraction technology for the detection and analysis of circulating tumor DNA tests. It also offers services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies and clinical trial support and specific oncogenic alterations. Biocept was founded on May 12, 1997 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Advertising and Marketing
Mid-Day Market Update: Pinduoduo Falls After Q1 Results; Biocept Shares Jump
Midway through trading Monday, the Dow traded down 0.30 percent to 25,687.85 while the NASDAQ fell 1.23 percent to 7,720.10. The S&P also fell, dropping 0.43 percent to 2,847.15. Leading and Lagging Sectors Utilities shares rose by 0.6 percent on Monday. Meanwhile, top gainers in the sector included Spark Energy Inc (NASDAQ: SPKE), up 3 percent, and Just Energy Group Inc. (NYSE: JE), up 2 percent. In trading on Monday, information technology shares fell by 1.1 percent. Top Headline International Game T...
Cancer Diagnostic Company Biocept's Stock Doubles In Value: What You Need To Know
Shares of Biocept Inc (NASDAQ: BIOC), a molecular diagnostics company specializing in biomarker analysis of circulating tumor-associated DNA, are making a strong upward move Monday.
Seeking AlphaMay 8
Biocept, Inc. (BIOC) CEO Michael Nall on Q1 2019 Results - Earnings Call Transcript
Biocept, Inc. (NASDAQ:BIOC) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Kevin McCabe - LHA, Investor Relations Michael Nall - President and Chief Executive Officer Tim Kennedy - Senior Vice President of Operations and Chief Financial Officer Edwin Hendrick - Senior Vice President and Chief Commercial Officer Conference Call Participants Jason McCarthy - Maxim Group Operator Good day and welcome to the Biocept First Quarter Financial Results Conference Call. [Operato...
-$0.61 per share